RENEE DONEY STAPLETON MD, PHD
Prescription History 1689754657
Internal Medicine - Critical Care Medicine in Burlington, VT

NPI Status: Active since October 16, 2006

Contact Information

111 COLCHESTER AVE
BURLINGTON, VT
ZIP 05401
Phone: (802) 847-1158

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for RENEE DONEY STAPLETON MD, PHD, an active Critical Care Medicine specialist practicing in Burlington, VT. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 254 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 92 claims alone.


Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 24
30-Day Fills 33.7
Days Supply 906
VT State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills53.5
Peer Average Days Supply1,260
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,130.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$47.12

State Avg Cost Per Claim

$52.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 57
30-Day Fills 83.0
Days Supply 2,390
VT State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills25.9
Peer Average Days Supply318
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 159.1% higher than the standard regional baseline profile for VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,342.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.55

State Avg Cost Per Claim

$15.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Dupixent Pen

Generic Formulation: DupilumabSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 574
VT State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills27.0
Peer Average Days Supply754
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $76,033.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,620.64

State Avg Cost Per Claim

$4,320.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain skin conditions (eczema, prurigo nodularis) and a certain esophagus problem (eosinophilic esophagitis). It is also used along with other medications to help control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. In addition, dupilumab may be used to reduce symptoms caused by nasal polyps and the long-term swelling of the sinuses and nasal passage (chronic rhinosinusitis with nasal polyposis). Dupilumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-4 and interleukin-13) that may cause inflammation and swelling. This medication should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dupixent Syringe

Generic Formulation: DupilumabSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
VT State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills25.5
Peer Average Days Supply724
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $50,158.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,858.33

State Avg Cost Per Claim

$4,623.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain skin conditions (eczema, prurigo nodularis) and a certain esophagus problem (eosinophilic esophagitis). It is also used along with other medications to help control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. In addition, dupilumab may be used to reduce symptoms caused by nasal polyps and the long-term swelling of the sinuses and nasal passage (chronic rhinosinusitis with nasal polyposis). Dupilumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-4 and interleukin-13) that may cause inflammation and swelling. This medication should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 14
30-Day Fills 40.3
Days Supply 1,210
VT State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills73.9
Peer Average Days Supply2,179
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.3% less volume than the regional standard for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $245.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.55

State Avg Cost Per Claim

$19.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Nucala

Generic Formulation: MepolizumabSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 19
30-Day Fills 31.6
Days Supply 924
VT State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills26.5
Peer Average Days Supply749
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $119,811.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,305.89

State Avg Cost Per Claim

$5,029.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you do your normal activities and decreases time lost from work or school. Mepolizumab is also used to treat certain other immune system disorders (chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome). This medication works by decreasing a certain type of white blood cell (eosinophils). This effect helps reduce swelling (inflammation) of the airways to make breathing easier. It may also help reduce the size of nasal polyps, and lessen symptoms such as runny/stuffy nose, mucus in the throat, loss of smell, facial pain, and tiredness. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 14
30-Day Fills 36.0
Days Supply 1,080
VT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills39.3
Peer Average Days Supply1,177
Conservative Utilization

This provider writes prescriptions for this formulation 46.2% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,928.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$994.88

State Avg Cost Per Claim

$547.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 92
30-Day Fills 138.0
Days Supply 4,140
VT State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills36.1
Peer Average Days Supply1,074
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 228.6% higher than the standard regional baseline profile for VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $91,985.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$999.84

State Avg Cost Per Claim

$830.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like RENEE DONEY STAPLETON MD, PHD provides transparency into local medical care patterns within Burlington, VT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Critical Care Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.